- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Artificial Intelligence and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Georgios Symeonidis
Insights 13 results
Client Alert
Article · Source: The Guide to Life Sciences - Third Edition
August 14, 2024
European Union: Commission zeroes in on innovation in merger control and pay-for-delay cases
Article · Source: Law360
August 6, 2024
A Primer On EU's Updated Human Substance Regulations
Article · Source: LexisNexis Practical Guidance
May 6, 2024
The New EU Corporate Sustainability Reporting Directive: What Does It Mean For Non-EU Companies
Client Alert
January 31, 2024
The New EU Corporate Sustainability Reporting Directive: What Does It Mean For Non-EU Companies?
Article · Source: The Guide to Life Sciences - Second Edition
October 20, 2023
European Union: Commission Intensifies Merger Review Focus on Pipeline Products and Pay-for-Delay Cases in the Spotlight
Article · Source: Bioprocess Online
September 1, 2023
How To Navigate The EU's New Interim PSA Program
Client Alert
July 6, 2023
EUROPE – New Interim Guidance on Parallel EMA-HTA Body Scientific Advice
Client Alert
May 3, 2023
EUROPE – Revision of EU General Pharmaceutical Legislation
Client Alert
March 27, 2023
With Risk Comes Responsibility: EU Proposes High-Risk AI Regulation Affecting Device Manufacturers
Client Alert
December 19, 2022
EUROPE - Less Pharmaceutical Incentives On The Horizon
Article · Source: Law360
December 16, 2022
How EU's New Pharma Incentives May Affect US Cos.